NasdaqGS:RXRXBiotechs
Recursion Pharmaceuticals (RXRX) Is Down 5.5% After Q2 Revenue Drop And Narrower Losses - What's Changed
In the second quarter of 2026, Recursion Pharmaceuticals reported revenue of US$7.67 million, down from US$19.22 million a year earlier, while reducing its net loss to US$131.01 million compared with US$171.90 million.
Despite weaker top-line results, recent commentary highlighting Recursion’s AI-enabled drug discovery platform and advancing early-stage oncology trials has drawn attention to the company’s progress in industrializing drug development.
Now we’ll examine how Recursion’s...